MiMedx Group (MDXG) has entered a strategic collaboration with Vaporox to jointly promote and market their wound care products.
As part of the agreement, MiMedx has invested in Vaporox and secured certain exclusive rights for potential acquisition discussions. Vaporox's FDA-cleared Vaporous Hyperoxia Therapy (VHT) device, which combines ultrasonic mist and concentrated oxygen to treat chronic wounds, complements MiMedx's placental allografts. The partnership aims to offer clinicians broader solutions for hard-to-heal wounds such as diabetic foot ulcers and pressure ulcers.
MiMedx CEO Joseph Capper stated that the addition of VHT aligns with the company's diversification strategy and enhances treatment options for chronic wounds. Vaporox CEO Alan Sage added that the partnership would boost awareness and adoption of their device through MiMedx's market presence.
Clinical studies of VHT have shown over 80 percent healing rates at 20 weeks, and real-world use alongside MiMedx products has shown promising results.
Wednesday, MDXG closed at $6.52, down 2.25%, and rose to $7.44 in after-hours trading, up 14.11% on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.